NCT06359067Completed
A Real-World Study of Bispecific Antibodies in Multiple Myeloma
A Real-World Study of Bispecific Antibodies, Teclistamab and Elranatamab, for Patients With Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 11 Apr 2024
Brief summary (registry, in English)
Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 600 (actual)
- First submitted
- 25 Mar 2024
- Start date
- 1 Jul 2022
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Multiple myeloma
- NCT number
- NCT06359067
What you commit to
- Study type: Observational
- Participants enrolled: 600
- From 1 Jul 2022 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Patients opposed to the collection of their personal data
Who the study is looking for
- Adult ≥ 18 years old
- Patients with multiple myeloma
- Patients who received at least one administration of the following therapies: teclistamab, elranatamab
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assistance Publique-Hopitaux de Paris (AP-HP) Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.